anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
INTRODUCTION: Pregnancy in a woman with heart and chronic renal failure can lead to life-threatening complications for both mother and child. Although such cases are often delivered by cesarean section, few reports have described anesthesia methods.
CASE PRESENTATION: We encountered a case in which cesarean section was performed using combined spinal and epidural anesthesia for a pregnant woman with chronic renal and heart failure. The 35-year-old Japanese woman had been undergoing hemodialysis for several years. Heart failure symptoms that appeared during pregnancy initially improved with treatments such as increasing hemodialysis, but recurred. She was admitted to the intensive care unit. The initial plan was to deliver the baby after a few weeks, but further progression of heart failure became a concern. After a clinical conference among staff, a cesarean section with combined spinal and epidural anesthesia was scheduled for 24 weeks, 0 days of gestation. The anticoagulant for dialysis was also changed from heparin to nafamostat in preparation for cesarean section. Monitoring was started with central venous and radial artery pressures before induction of anesthesia. Combined spinal and epidural anesthesia was induced and the cesarean section was completed without complications. Surgery was initiated under continuous administration of phenylephrine, which was intended to avoid hypotension due to anesthesia. The hemodynamic and respiratory status of the patient remained stable postoperatively. After the cesarean section, morphine was administered epidurally and the epidural catheter was removed.
CONCLUSION: Cesarean section was safely performed for a pregnant woman with renal and heart failure using combined spinal and epidural anesthesia.
Chronic atrophic gastritis (CAG) is a prevalent preneoplastic condition of the stomach. Palmatine (PAL), an isoquinoline alkaloid isolated from Rhizoma Coptidis (RC), has significant anti-inflammatory properties and is often used to treat gastrointestinal disorders. However, the mechanism of PAL on CAG remains unclear. In this study, N-methyl-N'-nitrosoguanidine (MNNG) was used to induce CAG inflammatory disease models in vivo and in vitro. The efficacy of five alkaloids in RC and the dose-dependent effects of the most effective PAL in CAG mice were evaluated in two animal experiments. RNA-seq and western blot revealed that PAL significantly improved IL-17, TNF, and NF-kappa B inflammation-related signaling pathways. Further hub gene prediction and experimental validation revealed that PAL modulated the STAT1/CXCL10 axis, thereby exerting attenuation of CAG through the regulation of IL-17, TNF-α, and p-p65 expression. In conclusion, PAL was proposed to mitigate MNNG-induced CAG, potentially through the inhibition of oxidative stress and inflammatory responses via the STAT1/CXCL10 axis. This approach is an effective complement to the use of PAL in the treatment of CAG.
This study will look at oligomeric procyanidin complex (OPC) and vitamin D3. OPC is the major part of Grape Seed Extract (GSE). Researchers are in looking at the combination of GSE and vitamin D in subjects with solid cancers (gastrointestinal, lung, breast, prostate, lymphoma or cancer of the lymph nodes). Researchers will examine the safety of the GSE and vitamin D when GSE is given at different doses. Researchers will also look at the effects of GSE and vitamin D on your quality of life and your body. In particular, they will look at differences in biomarkers in your blood and urine.
PROBLEM TO BE SOLVED: To obtain a hair-restoring cosmetic safe for skins and having sufficient effects for restoring hair, preventing the falling of hair, etc., by formulating a specific capsaicin analogue, vanillyl amide derivative, in the form of its glycoside with a saccharide such as glucose, galactose, xylose or maltose. SOLUTION: This hair-restoring cosmetic contains at least one kind of glycoside expressed by the formula (G is a saccharide residue obtained from a monosaccharide or an oligosaccharide; R is a 8-11C saturate/unsaturated hydrocarbon). A vanillyl amide derivative for forming the glycoside is capsaicin, etc. The saccharide to be combined with the vanillyl amide derivative includes all of saccharides forming the glycosides, but preferably is a monosaccharide such as glucose or an oligosaccharide such as maltose from the aspects of easy availability, solubility in aqueous solvents, and endermic absorbability. The obtained glycoside is especially preferably a glucose glycoside, concretely capsaicin β-D-glucoside, etc. The glycoside is formulated in an amount of 0.1-10.0wt.% based on the cosmetic.
PURPOSE:A cardiac useful for remedying malum cordis, having positively inotropic action and an action on the increase of coronary blood stream, comprising a carbostyril derivative or its salt as an active ingredient. CONSTITUTION:The titled cardiac comprising a compound shown by the formulaI(R<1> is H, alkyl, alkenyl, alkynyl, or phenylalkyl; R<2> is H or alkoxy; R<3> is H, alkanoyl, furoyl, pyridylcarbonyl, alkanesulfonyl, alkyl, etc.) or its salt such as 6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-3,4-dihydrocarbostyril as an active ingredient. The compound shown by the formulaIdoes not increase heart rate or the degree of the increase in heart rate is extremely low. The compound shown by the formulaIis obtained by reacting a compound shown by the formula II with a compound shown by the formula III (X is halogn, alkanesulfonyloxy, etc.) in an inert solvent in the presence of a basic condensation agent.
Treatment of patients with post-intubation (post-tracheostomy) stenotic laryngotracheal lesions combined with tracheoesophageal fistula is the most difficult problem for various specialists. A 20-year-old patient received a severe concomitant injury with necessary prolonged mechanical ventilation and tracheostomy. Decannulation was followed by shortness of breath and cough with discharge of sputum mixed with liquid and food. Post-tracheostomy total cicatricial atresia of the larynx and cervical trachea combined with cricoid cartilage fracture, as well as tracheoesophageal fistula of cervical trachea was diagnosed. Tracheostomy and gastrostomy were performed. After 3-month rehabilitation, the patient admitted to the Vishnevsky National Medical Research Center of Surgery. After additional examination, the patient underwent circular laryngotracheal resection, closure of tracheoesophageal fistula, laryngotracheal reconstruction (laryngotracheal anastomosis by Grillo with thyroid cartilage repair), re-tracheostomy. A favorable outcome was obtained. In such patients, treatment strategy cannot be standardized and require a personalized approach.
The dosage of desmopressin acetate tablets must be determined for each individual patient and adjusted according to the diurnal pattern of response. Response should be estimated by two parameters: adequate duration of sleep and adequate, not excessive, water turnover. Patients previously on intranasal desmopressin acetate therapy should begin tablet therapy twelve hours after the last intranasal dose. During the initial dose titration period, patients should be observed closely and appropriate safety parameters measured to assure adequate response. Patients should be monitored at regular intervals during the course of desmopressin acetate tablet therapy to assure adequate antidiuretic response. Modifications in dosage regimen should be implemented as necessary to assure adequate water turnover. Fluid restriction should be observed. (See WARNINGS, PRECAUTIONS, Pediatric Use and Geriatric Use.) 

### Adults and Children

It is recommended that patients be started on doses of 0.05 mg (1/2 of the 0.1 mg tablet) two times a day and individually adjusted to their optimum therapeutic dose. Most patients in clinical trials found that the optimal dosage range is 0.1 mg to 0.8 mg daily, administered in divided doses. Each dose should be separately adjusted for an adequate diurnal rhythm of water turnover. Total daily dosage should be increased or decreased in the range of 0.1 mg to 1.2 mg divided into two or three daily doses as needed to obtain adequate antidiuresis. See Pediatric Use subsection for special considerations when administering desmopressin acetate to pediatric diabetes insipidus patients.
Patients will be treated with the 4-drug chemo-immunotherapy regimen. Cycles are a minimum of 28 days.
The invention discloses a coptis and radix sophorae flavescentis anti-dysenteric particle as well as a preparation method and an application of the coptis and radix sophorae flavescentis anti-dysenteric particle and aims at solving the problems that livestock and poultry can generate medicine resistance on the exiting medicine, and meanwhile, the medicine residue can be caused. The particle is prepared from the following ingredients in parts by weight: 400 parts of coptis, 90 parts of radix sophorae flavescentis, 300 parts of Chinese pulsatilla root, 90 parts of myrobalan and 120 parts of liquorice. The recipe of the coptis and radix sophorae flavescentis anti-dysenteric particle is reasonable, the raw medical material resources are wide, the prepared products are mainly used for treating livestock and poultry dampness-heat of liver and gallbladder, heart and stomach fire, damp and hot dysentery, lingering dysentery, piglet white scour and yellow scour, and has the effects of clearing away heat to moisten dryness, purging fire to remove toxin and relieving diarrhea with astringents. Clinic tests prove that the curative effect is exact. The production process selected by in the preparation method provided by the invention has a short production period, the production cost is low, the operation is easy, in addition, active ingredients of raw medical materials are extracted to the furthest degree, and the curative effect of the produced products is stable. Meanwhile, the preparation selected for the coptis and radix sophorae flavescentis anti-dysenteric particle can adapt to the market requirements and the medication habits, and the transportation and the storage are also very convenient.
As with all therapeutic proteins, there is a potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and the specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors, including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies in the studies described below with the incidence of antibodies in other studies or to other bevacizumab products may be misleading. 

In clinical studies for adjuvant treatment of a solid tumor, 0.6% (14/2233) of patients tested positive for treatment-emergent anti-bevacizumab antibodies as detected by an electrochemiluminescent (ECL) based assay. Among these 14 patients, three tested positive for neutralizing antibodies against bevacizumab using an enzyme-linked immunosorbent assay (ELISA). The clinical significance of these anti-bevacizumab antibodies is not known.
BACKGROUND AND OBJECTIVES: Glioblastoma multiforme (GBM) is one of the most aggressive cancers of the central nervous system. It is characterized by a high mitotic activity and an infiltrative ability of the glioma cells, neovascularization and necrosis. GBM evolution entails the continuous interplay between heterogeneous cell populations, chemotaxis, and physical cues through different scales. In this work, an agent-based hybrid model is proposed to simulate the coupling of the multiscale biological events involved in the GBM invasion, specifically the individual and collective migration of GBM cells and the concurrent evolution of the oxygen field and phenotypic plasticity. An asset of the formulation is that it is conceptually and computationally simple but allows to reproduce the complexity and the progression of the GBM micro-environment at cell and tissue scales simultaneously.
METHODS: The migration is reproduced as the result of the interaction between every single cell and its micro-environment. The behavior of each individual cell is formulated through genotypic variables whereas the cell micro-environment is modeled in terms of the oxygen concentration and the cell density surrounding each cell. The collective behavior is formulated at a cellular scale through a flocking model. The phenotypic plasticity of the cells is induced by the micro-environment conditions, considering five phenotypes.
RESULTS: The model has been contrasted by benchmark problems and experimental tests showing the ability to reproduce different scenarios of glioma cell migration. In all cases, the individual and collective cell migration and the coupled evolution of both the oxygen field and phenotypic plasticity have been properly simulated. This simple formulation allows to mimic the formation of relevant hallmarks of glioblastoma multiforme, such as the necrotic cores, and to reproduce experimental evidences related to the mitotic activity in pseudopalisades.
CONCLUSIONS: In the collective migration, the survival of the clusters prevails at the expense of cell mitosis, regardless of the size of the groups, which delays the formation of necrotic foci and reduces the rate of oxygen consumption.
Group one will be instructed to administer their last dose of enoxaparin at 07:00 in the morning on the day prior to their scheduled surgery date. This will mean that patients who have their surgery scheduled for 07:00 the following day will be 24-hours removed from their last dose. Patients presenting for surgery later in the day would be slightly farther removed from their last dose, however this is currently considered normal clinical practice.
As a method of measuring a sectional figure of a living body by using a resonance medium in the living body, a MRI device has been introduced. However, the MRI device is not applied to bones, teeth which are poor in resonance-related protons, electrons and molecules. According to the invention, electrical, magnetic and electromagnetic fields are applied to the bones and teeth using a resonance medium. By using the resonance of the resonance medium, figure and displacement of the bones and teeth are measured. In more detail, proton spin and electric spin are applied to the bones and the teeth so that the spin state is measured to specify the figure and displacement by means of the MRI device. Otherwise, a resonance circuit which comprises the resonance medium is applied to the bones and teeth which changes rotationally and linearly. The resonance circuit changes its resonance frequency according to the displacement of articles to be measured. As one example, LC resonance circuit is exemplified which changes its inductance and capacitance, and an antenna circuit which changes the length. 
Frequency which is changed by an oscillating circuit is applied to the resonance circuit. The resonance frequency is read out by an output change from the oscillating circuit influenced by the resonance of the resonance circuit. On the basis of the resonance frequency of the resonance circuit, the displacement of the article are measured. Alternatively, an echo-back method may be applied.
PURPOSE: Nonalcoholic steatohepatitis (NASH) has been an increasingly significant contributor to hepatocellular carcinoma (HCC). Understanding the progression from NASH to HCC is critical to early diagnosis and elucidating the underlying mechanisms.
RESULTS: 5 significant prognostic genes related to NASH-HCC transformation were identified through algorithm selection, which were ME1, TP53I3, SOCS2, GADD45G and CYP7A1. A diagnostic model for NASH prediction was established (AUC=0.988). TP53I3 and SOCS2 were selected as potential critical genes in the progression of NASH-HCC by external dataset validation and in vitro experiments on NASH and HCC cell lines. Immune infiltration analysis illustrated the correlation between 5 significant prognostic genes and immune cells. Single-cell analysis identified hepatocytes related to NASH-HCC transformation markers, revealing their promoting role in the transformation from NASH to HCC.
CONCLUSION: With bulk-seq analysis and single-cell analysis, 5 significant prognostic genes related to NASH-HCC transformation were identified and validated at both dataset and in vitro experiment level. Among them, TP53I3 and SOCS2 might be potential critical genes in NASH-HCC progression. Single-cell analysis identified and revealed the critical role that NASH-HCC related hepatocytes play in NASH-HCC tansformation. Our research may introduce a new perspective to the diagnosis, treatment of NASH-related HCC.
Patients with hepatocellular carcinoma (HCC) who undergo curative hepatectomy may experience varying remnant liver volumes. The investigators aimed to evaluate whether the extent of liver resection has an effect on postoperative recurrence in HCC patients. A retrospective analysis was conducted on 197 patients who underwent hepatectomy for a solitary HCC lesion measuring ≥5 cm between January 2019 and June 2022. Patients were divided into major hepatectomy (MAH) group (n=70) and minor hepatectomy (MIH) group (n=127) based on the extent of liver resection. Recurrence-free survival (RFS) was compared between the two groups. Propensity score matching was employed to mitigate potential biases in this research.
BACKGROUND AND AIMS: Clinical trials suggest that glucagon-like peptide-1 (GLP-1) receptor agonists may have beneficial effects on NAFLD, but the impact on hard hepatic end points is unknown. We assessed the association between the use of GLP-1 receptor agonists and the risk of serious liver events in routine clinical practice.
APPROACH AND RESULTS: Cohort study using data from nationwide registers in Sweden, Denmark, and Norway, 2007-2020, including 91,479 initiators of GLP-1 receptor agonists and 244,004 initiators of the active comparator, dipeptidyl peptidase-4 inhibitors, without a history of chronic liver disease other than NAFLD/NASH. The primary outcome was serious liver events: a composite of incident compensated and decompensated cirrhosis and HCC. Secondary outcomes were the individual components of the primary outcome. Cox regression was used to estimate HRs, using propensity score weighting to control for confounding. Users of GLP-1 receptor agonists had 608 serious liver events (adjusted incidence rate: 16.9 events per 10,000 person-years), compared with 1770 events among users of dipeptidyl peptidase-4 inhibitors (19.2 events per 10,000 person-years). The adjusted HR was 0.85 (95% CI: 0.75 to 0.97), and the rate difference was -2.1 (-4.4 to 0.1) events per 10,000 person-years. In secondary outcome analyses, the adjusted HR was 0.85 (0.75 to 0.97) for compensated and decompensated cirrhosis and 1.05 (0.80 to 1.39) for HCC.
CONCLUSIONS: The use of GLP-1 receptor agonists was associated with a significantly reduced risk of serious liver events, driven by a reduction of compensated and decompensated cirrhosis.
PCT No. PCT/DE94/00879 Sec. 371 Date Sep. 5, 1995 Sec. 102(e) Date Sep. 5, 1995 PCT Filed Jul. 19, 1994 PCT Pub. No. WO95/03061 PCT Pub. Date Feb. 2, 1995The invention relates to a preparation for improving the blood supply. The problem with prior art preparations or processes resides in the fact that soft magnetic components had to be introduced into the body in capsule form or a magnetic field had to be applied after the application of demagnetized particles to the skin. The purpose of the invention is to provide a novel preparation for improving the blood supply in which special hard magnetic particles are used. According to the invention, the preparation for improving the blood supply consists of a pharmaceutically or cosmetically acceptable medium and possibly further additives containing finely distributed hard magnetic single-grade particles with a high coercitive field intensity and grain sizes in the range of 600 to 1200 nm. Dispersions of this preparation exhibit no aggregation of the hard magnetic particles. The preferred use is in the cosmetic and dermatological field.
PURPOSE OF REVIEW: This review examines the most common circadian rhythm disorder in adolescents, delayed sleep phase disorder. It explores the etiology, prevalence, clinical features, diagnostic tools and criteria, and treatment options to identify sleep disorders early in the course. This is important to help improve youths in terms of education and quality of life.
RECENT FINDINGS: Recent studies indicate that delayed sleep wake phase disorder has a range of prevalence between 1% and 16%. It is often associated with neurodevelopmental disorders (i.e. attention deficit hyperactivity disorder and autism spectrum disorder) as well as psychopathology (i.e. substance use, anxiety, and depression). It can present with a myriad of symptoms, such as insomnia, restless sleep, and poor daytime cognitive function, often seen in pediatric practice. Important diagnostic measures incorporate history-taking, sleep logs, actigraphy (i.e. Apple watches) and measurement of dim light melatonin onset. Treatments include improved sleep hygiene, chronotherapy, exogenous melatonin administration, and bright light therapy.
SUMMARY: There are many environmental and genetic factors that can predispose an individual to circadian rhythm disorders. Delayed sleep phase disorder has detrimental effects on overall health, cognition, and behavior. It is important to screen for this disorder in routine pediatric clinic visits. The goal of early intervention is to prevent health and behavioral complications and treat adolescents using a multimodal approach, especially those with affective/neurodevelopmental conditions, who are prone to having delayed sleep wake phase disorder.